Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18947394 | 0.90 | HCRTR1 (0.39) | PDE10AGSK3BKMT2AMEN1DHFR | |
| SCHEMBL19049064 | 0.86 | PDE10A (0.48) | PDE10AGSK3BKMT2AMEN1 | |
| SCHEMBL19002463 | 0.84 | EPHX2 (0.42) | KMT2AMEN1CYP2C9 | |
| SCHEMBL18947444 | 0.84 | BLM (0.40) | KMT2AMEN1 | |
| SCHEMBL21901063 | 0.83 | PDE10A (0.46) | PDE10AGSK3BKMT2AMEN1 | |
| SCHEMBL19002473 | 0.83 | PDE10A (0.46) | PDE10AGSK3BKMT2AMEN1ALDH1A1 | |
| SCHEMBL18947216 | 0.82 | EPHX2 (0.43) | GSK3BKMT2AMEN1ALDH1A1CYP2C9 | |
| SCHEMBL19002562 | 0.82 | GSK3B (0.43) | GSK3BKMT2AMEN1 | |
| SCHEMBL18947393 | 0.80 | BLM (0.37) | KMT2AMEN1 | |
| SCHEMBL19002456 | 0.79 | BLM (0.47) | GSK3BKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | PDE10A 1360/4885GSK3B 294/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.